Pharmaceuticals News and Research

RSS

FDA approves Brintellix drug to treat depressive disorder in adults

The U.S. Food and Drug Administration today approved Brintellix (vortioxetine) to treat adults with major depressive disorder.

1 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

Merck Canada Gives Patient-Oriented Research $4M Boost

...

30 Sep 2013

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND for Oral Suspension.

30 Sep 2013

A*STAR, NSC and NTU to expand skin research in Singapore

Singapore is committing close to S$100 million to skin research, with the announcement of the Skin Research Institute of Singapore. A collaboration between the Agency for Science Technology and Research, National Skin Centre and Nanyang Technological University, the SRIS will harness the expertise of scientists, clinicians and engineers to foster and conduct high impact, inter-disciplinary skin research designed to translate into improved health outcomes and quality of life.

30 Sep 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

Innovative packaging design aids convergence in the pharmaceutical industry

PCI, a global supplier of pharmaceutical commercial packaging solutions and clinical trials services, announces the availability of a white paper detailing how it’s innovative packaging design aids convergence in the pharmaceutical industry.

30 Sep 2013

New treatment methods aim to help people reduce binge-eating behavior

Two new treatment methods under investigation at Drexel University aim to help people reduce binge-eating behavior.

30 Sep 2013

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

...

26 Sep 2013

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Ampio Pharmaceuticals announces financing transaction of $25 million

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a financing transaction that will provide $25 million in gross proceeds to the Company. The financing is a registered direct placement of common stock of the Company.

26 Sep 2013

Designing safer titanium dioxide for human use

Using a particular type of titanium dioxide - a common ingredient in cosmetics, food products, toothpaste and sunscreen - could reduce the potential health risks associated with the widely used compound. The report on the substance, produced by the millions of tons every year for the global market, appears in the ACS journal Chemical Research in Toxicology.

26 Sep 2013

Federal Data Shows R&D Spending Slide

...

25 Sep 2013

Amgen Plans R&D Center In China

...

25 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

Battle brewing over new regulations for compounding pharmacies

In addition, a bill that would require professional drivers to be tested for sleep apnea flies through the House.

25 Sep 2013

Cardiome partners with LifePharma to commercialize BRINAVESS in Cyprus

Cardiome Pharma Corp. today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Cyprus.

24 Sep 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

First Edition: September 24, 2013

Today's headlines include reports about Senate action on the effort to defund the health law as well as a scheduled appearance by former President Bill Clinton and President Barack Obama to kick off the roll out of a key part of the overhaul.

24 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013